Chemistry:4-Chlorophenylisobutylamine

From HandWiki
Short description: Entactogen and stimulant drug of the phenethylamine class
4-Chlorophenylisobutylamine
4-Chlorophenylisobutylamine.png
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • Uncontrolled (but may be covered under the Federal Analogue Act in the United States and under similar bills in other countries)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC10H14ClN
Molar mass183.68 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

4-Chlorophenylisobutylamine (4-CAB, AEPCA), also known as 4-chloro-α-ethylphenethylamine, is an entactogen and stimulant drug of the phenethylamine class.[1] It is an analogue of para-chloroamphetamine (PCA) where the alpha position methyl has been replaced with an ethyl group.[1]

In comparison to PCA, 4-CAB is approximately 2- and 5-fold less potent at inhibiting the reuptake of serotonin (IC50 = 330 nM) and dopamine (IC50 = 2,343 nM), respectively, and is about 3-fold less potent in substituting for MDMA in animals in drug discrimination assays.[1] Though its dopaminergic activity is significantly attenuated compared to PCA, unlike the case of MBDB, it is not abolished[clarification needed], and is actually similar to that of MDMA.[1]

Relative to PCA, 4-CAB is also substantially less effective as a serotonergic neurotoxin.[1] A single 10 mg/kg administration of PCA to rats produces an approximate 80% decrease in serotonin markers as observed 1 week later.[1] In contrast, 11 mg/kg and 22 mg/kg doses of 4-CAB result in only 20% and 50% decreases, respectively.[1] This is once again similar to MDMA which causes a 40-60% reduction with a single 20 mg/kg dose.[2]

See also

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Behavioral, biochemical and neurotoxicological actions of the alpha-ethyl homologue of p-chloroamphetamine". European Journal of Pharmacology 191 (1): 1–10. November 1990. doi:10.1016/0014-2999(90)94090-K. PMID 1982656. 
  2. "Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity". NeuroReport 10 (17): 3675–80. November 1999. doi:10.1097/00001756-199911260-00039. PMID 10619665.